AUA Quality Improvement Summit: Opioid Stewardship in Urology (2018)

December 8, 2018

The opioid epidemic in America is an urgent public health crisis.  According to the CDC, nearly two million Americans have a prescription-related opioid use disorder, and 46 people die from a prescription opioid-related overdose every day. While many entities are looking at this problem holistically, no one is looking at how urologic care may be contributing to the problem and how urologists can be part of the solution.

While everyone is aware of the opioid problem, attention has not been given to urology's contribution to this problem.  There are many treatment plans which currently utilize opioid prescriptions, but alternatives may be just as effective.  The Summit will allow the sharing of such alternatives and their effectiveness.  Additionally, there are discrepancies in on opioid dosage for urologic conditions.  While each patient is different, conversations should begin to standardize appropriate dosages.  Lastly, urologists should learn how to address patients' request for opioids when perhaps alternatives are more appropriate.

Target Audience

This course is designed for:

  • Urologists
  • Residents
  • Advanced Practice Providers
  • Medical Students
  • Research/Scientists 

Learning Objectives

After completing this activity, particpants will be able to:

  1. Explain the opioid epidemic in the context of surgical management of urologic diseases
  2. Describe steps that can be taken by urologists to influence the opioid epidemic 
  3. Delineate roles urologists can play in combating epidemic 
  4. Identify opportunities to propose or implement new policies to combat the opioid epidemic. 
     
Course summary
Available credit: 
  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Non-Physician Participation
Course opens: 
12/08/2018
Course expires: 
12/08/2021
Event starts: 
12/08/2018 - 7:30am
Event ends: 
12/08/2018 - 3:30pm
Rating: 
0

AUA Quality Improvement Summit: Opioid Stewardship in Urology

December 8, 2018

7:30 – 8:00 AM           Registration and Breakfast

8:00 – 8:15 AM           Opening Remarks

8:15 – 9:00 AM           Keynote

  • The Role of Physicians and Prescription Pharmaceuticals in the Opioid Epidemic (Chad Brummett, MD, University of Michigan)

9:00 – 10:00 AM         Session 1: Physician-led Multicomponent Interventions in Opioid Stewardship

  • Procedure-specific opioid prescribing guidelines (Richard J. Barth, MD, Dartmouth University)
  • Opioid reclamation efforts (Jonah Stulberg, MD, PhD, MPH, Northwestern Medicine)
  • MUSIC and opioid stewardship (Jim Dupree, MD, University of Michigan)

10:00 – 11:15 AM       Session 2: Understanding Postoperative Pain

  • Pathophysiology of Post-operative Pain (Brooke Chidgey, MD, University of North Carolina)
  • Complementary Alternative Medicine Pain Management Strategies (Meghan Sperandeo-Fruge, ND, National University of Natural Medicine)
  • Cognitive Behavioral Therapy and Other Non-Pharmacologic Approaches to Pain Management (Margaret Rukstalis, MD, Wake Forest School of Medicine)

11:15 – 12:00 PM       Urology Perspectives          

  • Challenging Urology Cases in Opioid Management (Moderator: Tudor Borza, University of Michigan; Panel Members: Vernon Pais, MD, Dartmouth; Benjamin Davies, MD, UPMC; Matthew E. Nielsen, MD, University of North Carolina)

12:00 – 12:15 PM       Lunch Break

12:15 – 1:00 PM         Urology Perspectives (continued)

1:00 – 2:00 PM           Session 3: High-Risk Patients and Expectations

  • Expectation Setting for Opioid Prescribing (Behfar Ehdaie, MD, Memorial Sloan Kettering)
  • A Surgeon’s Role in the Management of Opioid Misuse Disorders (Margaret Rukstalis, MD, Wake Forest School of Medicine)
  • The Role of Pain Specialists for Managing High-Risk Patients (Brooke Chidgey, MD, University of North Carolina)

2:00 – 3:00 PM           Session 4: Policy and Outreach

  • Opioid Education and Outreach (Jennifer Waljee, MD, MPH, MS, University of Michigan)
  • Policy Change/Legislature to Address the Opioid Crisis (Greg Murphy, MD, North Carolina General Assembly)
  • Opioid Prescribing and the FDA Safe Use Initiative (Scott Winiecki, MD, Food and Drug Administration)

3:00 – 3:30 PM           Closing Remarks: Timothy Averch, MD, Quality Improvement and Patient Safety Committee Chair

AUA Headquarters
Linthicum, MD 21090
United States

Name

Company

Role

Financial

Gregory B. Auffenberg, MD

Nothing to disclose

  

Timothy David Averch, MD

Canadian Journal of Urology

Health Publishing

Yes

 

Journal of Endourology

Health Publishing

No

Richard Barth

Nothing to disclose

  

Jennifer Bertsch

Nothing to disclose

  

Tudor Borza

Nothing to disclose

  

Chad Brummett, MD

Recro Pharma Inc.

Consultant or Advisor

Yes

 

Heron Therapeutics

Consultant or Advisor

Yes

 

Peripheral Perineural Dexmedetomidine

Owner, Product Development

Yes

 

NIH

Other

Yes

 

NIDA

Other

Yes

 

MDHHS

Other

Yes

Christi Marie Butler, MD

Nothing to disclose

  

Brooke Chidgey, MD

Nothing to disclose

  

Benjamin John Davies MD

Nothing to disclose

  

James M. Dupree IV, MD

Procter and Gamble

Investment Interest

No

 

Blue Cross Blue Shield of Michigan

Leadership Position

Yes

 

Lipocine

Investment Interest

No

 

American Urological Association

Consultant or Advisor

Yes

Behfar Ehdaie, MD

Myriad Genetics, Inc

Meeting Participant or Lecturer

Yes

 

InSightec

Meeting Participant or Lecturer, Scientific Study or Trial

No

Julia B. Finkelstein

Nothing to disclose

  

Elizabeth A. Green MD

Nothing to disclose

  

Tracey Lynn Krupski, MD

Argos

Scientific Study or Trial

No

 

FKD - Instilidrin

Scientific Study or Trial

No

 

American Cancer Society

Scientific Study or Trial

Yes

 

NIH

Scientific Study or Trial

No

Tim Large, M.D.

Nothing to disclose

  

Gregory Francis Murphy, MD

Nothing to disclose

  

Vikram M. Narayan, M.D.

Nothing to disclose

  

Matthew Edward Nielsen, M.D.

American College of Physicians High Value Care Task Force

Consultant or Advisor

Yes

 

Grand Rounds, Inc

Consultant or Advisor

Yes

 

American College of Physicians

Consultant or Advisor

Yes

Victor William Nitti, MD

Astellas

Health Publishing, Scientific Study or Trial

No

 

Allergan

Health Publishing, Scientific Study or Trial

No

 

Serenity Pharmeuticals

Investment Interest

Yes

 

Medtronic

Scientific Study or Trial

No

Vernon M. Pais Jr., MD

Clinical Nephrology

Health Publishing

No

Suzanne Boland Pope, MBA

Nothing to disclose

  

Margaret Rukstalis

Nothing to disclose

  

Angela M. Smith, MD, FACS, MS

AHRQ

Scientific Study or Trial

Yes

 

PCORI

Scientific Study or Trial

No

 

Merck

Consultant or Advisor

Yes

 

Photocure

Consultant or Advisor

Yes

Meghan Sperandeo-Fruge

Nothing to disclose

  

Jonah Stulberg, MD, PHD, FACS, MPH

Pacira Pharmaceuticals

Health Publishing, Scientific Study or Trial

Yes

 

National Institutes on Drug Abuse (NIDA)

Health Publishing, Scientific Study or Trial

Yes

 

Intuitive Surgical

Health Publishing, Meeting Participant or Lecturer

Yes

Ruchika Talwar, MD

Nothing to disclose

  

Jennifer Waljee, PHD

Nothing to disclose

  

Scott Winiecki, MD

Nothing to disclose

  

Anna Zampini, MD

Nothing to disclose

  

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 7.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Non-Physician Participation

Accreditation Period

Course opens: 
12/08/2018
Course expires: 
12/08/2021
Please login or register to take this course.

This activity is restricted to attendees of the AUA Quality Improvement Summit: Opioid Stewardship in Urology (2018).